CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
异基因造血干细胞移植在免疫治疗时代成人急性淋巴细胞白血病治疗中的作用
英文原题：Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy.
查看英文原题
Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
异基因造血干细胞移植（allo-HSCT）目前是成人急性淋巴细胞白血病（ALL）患者的标准治疗。近年来，随着免疫治疗的不断发展，如CAR-T 细胞、blinatumomab和inotuzumab ozogamicin，一系列重要的临床研究已证实其对ALL具有高缓解率和良好结局。尽管免疫治疗的出现扩大了复发/难治性（r/r）ALL患者接受allo-HSCT的机会，但allo-HSCT也伴随着潜在挑战。本综述将讨论免疫治疗时代allo-HSCT在成人ALL治疗中的作用。
展开英文摘要原文
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the standard of care for adult acute lymphoblastic leukemia (ALL) patients. In recent years, with the continuous development of immunotherapy, such as chimeric antigen receptor T cells, blinatumomab, and inotuzumab ozogamicin, a series of vital clinical studies have confirmed its high response rate and favorable outcomes for ALL.
Although the emergence of immunotherapy has expanded relapsed or refractory (r/r) ALL patients' opportunities to receive allo-HSCT, allo-HSCT is associated with potential challenges. In this review, the role of allo-HSCT in the treatment of adult ALL in the era of immunotherapy will be discussed.
论文信息
- 作者
- Sun W、Huang X
- 第一作者单位
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.China
- 文献类型
- 综述
- 期刊
- Chinese medical journal2022 Apr 20
- 原文标识
- PubMed 34890382 · DOI 10.1097/CM9.0000000000001898
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →